Literature DB >> 1627031

Herpes simplex virus associated with recurrent Stevens-Johnson syndrome. A management strategy.

P F Detjen1, R Patterson, G A Noskin, J P Phair, S O Loyd.   

Abstract

We describe a 36-year-old man with recurrent Stevens-Johnson syndrome, which became progressively more severe over a 13-year period. His episodes were apparently preceded by herpes simplex virus oral mucosal infections. A management protocol, including immediate therapy with acyclovir and prednisone at the onset of herpes simplex virus oropharyngitis, is outlined. This management strategy has successfully prevented four subsequent episodes of progression to Stevens-Johnson syndrome. Thus, Stevens-Johnson syndrome associated with herpes simplex virus may be prevented by early use of acyclovir and prednisone.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1627031

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  4 in total

1.  High-level human herpesvirus-6 viremia associated with onset of Stevens-Johnson syndrome: report of two cases.

Authors:  Amanda F Peppercorn; Melissa B Miller; David Fitzgerald; David J Weber; Pamela A Groben; Bruce A Cairns
Journal:  J Burn Care Res       Date:  2010 Mar-Apr       Impact factor: 1.845

2.  An atypical presentation of toxic epidermal necrolysis without mucosal involvement.

Authors:  Vikas Pathania; Sukriti Baveja; Anwita Sinha; J K Bhatia
Journal:  Med J Armed Forces India       Date:  2019-12-16

3.  Stevens-Johnson Syndrome and Herpes Simplex Type 1 Infection during Adalimumab Therapy for Crohn's Disease.

Authors:  Jenny Roselli; Tommaso Innocenti; Erica Nicola Lynch; Laura Parisio; Pasquale Apolito; Tommaso Mello; Giuseppe Macrì; Monica Milla; Maria Rosa Biagini; Mirko Tarocchi; Stefano Milani; Andrea Galli
Journal:  Case Rep Gastrointest Med       Date:  2020-04-15

4.  The psychological impact of Stevens-Johnson syndrome and toxic epidermal necrolysis on patients' lives: a Critically Appraised Topic.

Authors:  P O'Reilly; C Kennedy; P Meskell; A Coffey; I Delaunois; L Dore; S Howard; B Ramsay; C Scanlon; D M Wilson; B Whelan; S Ryan
Journal:  Br J Dermatol       Date:  2020-01-11       Impact factor: 9.302

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.